The venture financing and AMED grant funding position CORE to accelerate development of novel lineage-based oncology therapies for patients around the world.

风险投资和AMED资助使CORE能够加速开发面向全球患者的新型谱系导向肿瘤疗法。

BOSTON and TOKYO and SUZHOU, China

波士顿、东京以及中国苏州

,

，

July 28, 2026

2026年7月28日

/PRNewswire/ -- CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners.

/美通社/ -- 专注于谱系导向型精准肿瘤疗法的生物技术公司CORE Biomedicine今日宣布完成2100万美元的A轮融资。本轮融资由东京大学创新平台株式会社（UTokyo Innovation Platform Co., Ltd.）和Elikon Venture共同领投，InnoPinnacle Fund、三菱UFJ资本株式会社（Mitsubishi UFJ Capital Co., Ltd.）、苏州资本集团有限公司（Suzhou Capital Group Co., Ltd.）、CD Capital、元生创投（YuanBio Venture Capital）、Vision Incubate Co., Ltd.以及Root Venture Partners参与投资。

CORE's lineage-based approach is designed to identify and target core oncology drivers with precision while expanding the potential patient populations that may benefit from these novel therapies..

CORE基于谱系的方法旨在精准识别并靶向核心肿瘤驱动因子，同时扩大可能从这些新型疗法中受益的患者人群。

In addition to venture financing, CORE Biomedicine Japan, a wholly owned subsidiary, has been awarded a grant under the Strengthening Program for Pharmaceutical Startup Ecosystem, a highly competitive initiative run by the Japan Agency for Medical Research and Development (AMED) to accelerate innovative biotech companies and support Japan's biopharma ecosystem.

除风险投资融资外，全资子公司CORE Biomedicine Japan还获得了“制药初创企业生态系统强化计划”下的资助。该计划由日本医疗研究开发机构（AMED）运作，竞争极为激烈，旨在加速创新型生物科技公司的发展并支持日本的生物医药生态系统。

This grant supports CORE's research and development activities while strengthening collaborations through partnerships with Japanese universities, hospitals and the overall biopharma community..

本资助支持CORE的研发活动，同时通过与日本高校、医院及整个生物医药产业界的合作来加强协作。

These resources will advance CORE's lead programs through discovery and early clinical development. CORE is building an innovative precision medicine company by leveraging the rapidly evolving global biotech ecosystem.

这些资源将通过发现研究和早期临床开发，推动CORE的领先项目。CORE正通过利用快速发展的全球生物技术生态系统，打造一家创新的精准医疗公司。

'

'

This venture financing and AMED's support represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines,' said Dr. Ping Zhu, Co-Founder and CEO of CORE Biomedicine. 'We are grateful to our investors and partners as we advance our programs toward the clinic with the goal of bringing transformative therapies to patients globally.'.

“此次风险融资以及AMED的支持，是CORE Biomedicine的一个重要里程碑，也验证了我们对新一代肿瘤药物的愿景。”CORE Biomedicine联合创始人兼首席执行官朱平博士表示。“在我们将项目推进至临床阶段、旨在为全球患者带来变革性疗法的过程中，我们感谢我们的投资者和合作伙伴。”

'

'

CORE Biomedicine's lineage-based approach addresses a fundamental challenge in cancer biology that genomics alone cannot solve,' said Makoto (Mark) Ohori, PhD, Partner and Chief Investment Officer, Life Sciences, UTokyo Innovation Platform Co., Ltd. 'We are proud to co-lead this financing and look forward to supporting the CORE Biomedicine team as they advance their programs toward the clinic.'.

“CORE Biomedicine基于谱系的方法解决了癌症生物学中一个仅靠基因组学无法解决的根本性挑战，”东京大学创新平台公司生命科学合伙人兼首席投资官Makoto (Mark) Ohori博士表示。“我们很荣幸能共同主导此次融资，并期待在CORE Biomedicine团队推进其项目向临床应用迈进的过程中提供支持。”

'Elikon Venture highly recognizes the CORE Biomedicine team for their distinctive insights and extensive R&D experience in oncology area. We are delighted to witness the company's fast-growing trajectory. We look forward to collaborating with CORE Biomedicine to advance its cutting-edge drug pipeline and address unmet medical needs for global patients by delivering better clinical benefits.'.

“Elikon Venture 高度认可 CORE Biomedicine 团队在肿瘤领域的独特见解和丰富的研发经验。我们很高兴看到公司快速发展的轨迹。我们期待与 CORE Biomedicine 合作，推动其前沿药物管线的进展，通过提供更好的临床效益来满足全球患者未满足的医疗需求。”

About CORE Biomedicine

关于CORE生物医学

Founded by former leaders of H3 Biomedicine, CORE Biomedicine is developing the next generation of precision medicines by going beyond genomics. The company's lineage-based therapeutic approach targets core biological pathways that define cancer cell identity, enabling the discovery of first- and best-in-class therapies with the potential to benefit broader patient populations..

CORE Biomedicine 由 H3 Biomedicine 的前领导层创立，致力于通过超越基因组学的范畴，开发下一代精准药物。该公司基于谱系的疗法瞄准定义癌细胞身份的核心生物通路，从而有望发现首创和同类最优的疗法，使更广泛的患者群体受益。

About UTokyo Innovation Platform Co., Ltd. (UTokyo IPC)

关于东京大学创新平台株式会社（UTokyo IPC）

UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) is a venture capital firm wholly owned by the University of Tokyo, established in 2016 to strengthen Japan's global industrial competitiveness through startup investment and ecosystem building. UTokyo IPC supports the creation and growth of university-affiliated startups through investment and ecosystem-building activities..

东京大学创新平台株式会社（UTokyo IPC）是东京大学全资拥有的风险投资公司，成立于2016年，旨在通过创业投资和生态系统建设增强日本的全球产业竞争力。UTokyo IPC 通过投资和生态系统建设活动，支持大学关联初创企业的创建与成长。

About Elikon Venture

关于 Elikon Venture

Founded in 2021, Elikon Venture is a global early-stage biotech investor dedicated to addressing unmet clinical needs. We partner with ambitious entrepreneurs and pioneering scientists, bringing breakthrough technologies. Elikon brings unique insights to the biopharma market and specialize in connecting our global portfolio companies to China's top-tier industry resources and strategic services..

艾利康创投成立于2021年，是一家全球性的早期生物科技投资机构，致力于满足尚未被解决的临床需求。我们与富有雄心的创业者和开拓性的科学家合作，推动突破性技术的发展。艾利康为生物医药市场提供独特的洞察，并专注于将我们的全球投资组合公司与中国顶尖的行业资源和战略服务相连接。

SOURCE CORE Biomedicine

来源核心 生物医学

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示